GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for Jemperli for the treatment of patients with locally advanced mismatch repair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback